Drug treatment of depression in the 2000s:: An overview of achievements in the last 10 years and future possibilities

被引:29
|
作者
Baghai, Thomas C.
Volz, Hans-Peter
Moeller, Hans-Juergen
机构
[1] Univ Munich, Dept Psychiat, D-8000 Munich, Germany
[2] Krankenhaus Psychiat Psychotherapie & Psychosomat, Werneck, Germany
来源
关键词
depression; antidepressants; clinical trials; pharmacotherapy; new developments;
D O I
10.1080/15622970601003973
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
During the past 10 years our knowledge about the pharmacotherapy of depression has been consolidated, and a variety of very interesting new compounds launched onto the market. The pipeline of the pharmaceutical industry is still filled with an assortment of new developments and very promising new approaches towards the pharmacotherapy of depressive disorders. Future pharmacological treatments of depression will not only enhance serotonergic and noradrenergic neurotransmission: other systems, such as the melatonergic receptor system and the hypothalamus-pituitary-adrenal axis, are also the targets of newly developed and upcoming substances with putative antidepressant effects. The main advantages of the currently available newer pharmacotherapeutic options are the broadening of the spectrum of possible antidepressant treatments, which is of particular importance for the growing number of patients suffering from difficult-to-treat depression, and a far better tolerability profile in comparison to older compounds such as tricyclic antidepressants. Unresolved issues are the unacceptably high rate of non-responsiveness during antidepressant treatment, a latency of sometimes several weeks until clinical improvement and remission can be achieved, and a variety of possible side effects also present during treatment with modern compounds. This review mainly presents the development of antidepressant pharmacotherapies during the past 10 years, together with pharmacokinetic and pharmacodynamic information and a comparison of different pharmacological treatment principles evaluated in randomized controlled clinical trials. In addition, new pharmacological strategies that are not yet available on the market and strategies currently under development are reviewed in detail. The study of new treatment options is of major importance to provide better strategies for the clinical management of depression in the future, and is thus also of great socio-economic importance.
引用
收藏
页码:198 / 222
页数:25
相关论文
共 19 条
  • [1] Drug treatment of depression in the 1990s - An overview of achievements and future possibilities
    Moller, HJ
    Volz, HP
    [J]. DRUGS, 1996, 52 (05) : 625 - 638
  • [2] Drug treatment of Parkinson's disease in the 1990s - Achievements and future possibilities
    Hughes, AJ
    [J]. DRUGS, 1997, 53 (02) : 195 - 205
  • [3] Drug treatment of schizophrenia in the 1990s - Achievements and future possibilities in optimising outcomes
    Fleischhacker, WW
    Hummer, M
    [J]. DRUGS, 1997, 53 (06) : 915 - 929
  • [4] Microbiome Studies from Saudi Arabia over the Last 10 Years: Achievements, Gaps, and Future Directions
    Alzahrani, Khalid J.
    [J]. MICROORGANISMS, 2021, 9 (10)
  • [5] Drug treatment of rheumatic diseases in the 1990s - Achievements and future developments
    Choy, EHS
    Scott, DL
    [J]. DRUGS, 1997, 53 (03) : 337 - 348
  • [6] Patients operated for Duane's retraction syndrome - overview of the results in the last 10 years
    Jarc-Vidmar, Martina
    Gardasevic-Topcic, Ivana
    Kosec, Dragica
    [J]. ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2010, 79 : 86 - 88
  • [7] The Direction of Research and Management of Double-crested Cormorants Heading into the 2000s: Symposium Overview and Future Information Needs
    Dorr, Brian S.
    Somers, Christopher
    [J]. WATERBIRDS, 2012, 35 : 138 - 148
  • [8] Phylogeography's past, present, and future: 10 years after Avise, 2000
    Hickerson, M. J.
    Carstens, B. C.
    Cavender-Bares, J.
    Crandall, K. A.
    Graham, C. H.
    Johnson, J. B.
    Rissler, L.
    Victoriano, P. F.
    Yoder, A. D.
    [J]. MOLECULAR PHYLOGENETICS AND EVOLUTION, 2010, 54 (01) : 291 - 301
  • [9] Drug Treatment of Parkinson’s Disease in the 1990sAchievements and Future Possibilities
    Andrew J. Hughes
    [J]. Drugs, 1997, 53 : 195 - 205
  • [10] Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of depression: a critical appraisal of the last 10 years
    Rachid, F.
    Bertschy, G.
    [J]. NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY, 2006, 36 (03): : 157 - 183